Artrite Reumatóide

Rheum 2010; 62: 2569-2581 Over the last decade, the optimal use of disease modifying antirheumatic drugs (DMARDs) and the availability of new biologic agents have dramatically enhanced the success of RA management. Moreover, it has been recognized that early therapeutic intervention improves clinical outcomes and reduces the accrual of joint damage and disability. Undoubtedly, treating patients at a stage [...]

Keystone, E, Emery, P, Peterfy, C G, Tak, P P, Cohen, S, Genovese, M C, Dougados, M, Burmester, G R, Greenwald, M, Kvien, T K, Williams, S, Hagerty, D, Cravets, M W, Shaw, T Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Objective: To [...]

Bert Vander Cruyssen (Bert.VanderCruyssen@Ugent.be) Patrick Durez (Patrick.Durez@ruma.ucl.ac.be) Rene Westhovens (Rene.westhovens@uz.kuleuven.ac.be) Marie-Joelle Kaiser (Mjkaiser@chu.ulg.ac.be) Ilse Hoffman (Ilse.Hoffman@skynet.be) Filip De Keyser (Filip.Dekeyser@Ugent.be) The MIRA Study Group (not@valid.com) Abstract Introduction: This study describes the results of the Belgian “MabThera In Rheumatoid Arthritis (MIRA)” registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab. Methods: All Belgian rheumatologists [...]

Leigh D Church (L.D.Church@bham.ac.uk) Andrew D Filer (A.D.Filer@bham.ac.uk) Esther Hidalgo (Hidalgoester@gmail.com) Katherine A Howlett (K.A.Howlett@bham.ac.uk) Andrew MC Thomas (Andrew.Thomas@roh.nhs.uk) Stephen Rapecki (Stephen.Rapecki@ucb.com) Dagmar Scheel-Toellner (D.Scheel@bham.ac.uk) Christopher D Buckley (C.D.Buckley@bham.ac.uk) Karim Raza (k.raza@bham.ac.uk) Abstract: Introduction. Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to systematically analyse the phenotype, cytokine profile and frequency of interleukin-17 (IL-17) producing CD4-positive [...]

Sharon Van Doornum (svd@unimelb.edu.au) Caroline Brand (caroline.brand@mh.org.au) Vijaya Sundararajan (vijaya.sundararajan@med.monash.edu.au) Andrew E Ajani (andrew.ajani@mh.org.au) Ian P Wicks (ian.wicks@mh.org.au) Abstract Introduction: The 30-day case fatality rate after acute myocardial infarction (MI) for rheumatoid arthritis (RA) patients is twice that of the general population. This study compared the frequency and timeliness of early reperfusion therapy and treatment with secondary prevention medications after acute MI in [...]

Arthritis Research & Therapy Frederik Kreiner (frederik.kreiner@me.com) Henrik Galbo (hga@sund.ku.dk) Abstract Introduction: To elucidate in polymyalgia rheumatica (PMR) the role of tumor necrosis factor (TNF) α and the therapeutic potential of blockade with soluble TNF-α receptor, we carried out the first randomized controlled trial with etanercept in PMR. Methods: Twenty newly diagnosed, glucocorticoid (GC) naïve patients with PMR and 20 [...]

O abatacept, um membro de uma nova classe de fármacos que bloqueiam a acção das células do sistema imune, os linfócitos T, que estão envolvidos no processo inflamatório das articulações, mostrou-se eficaz no tratamento da artrite reumatóide. É esta a conclusão de uma nova revisão sobre a actuação deste fármaco efectuada pela Cochrane Collaboration, uma organização [...]

Publicado: quinta-feira, 1 de Outubro de 2009 21:30 Autor: Ronald F. van Vollenhoven Few, if any, areas of medical therapeutics have witnessed such dramatic changes as those that have occurred in the therapy of rheumatoid arthritis (RA) during the past two decades. Improvements in clinical trials methodologies, the introduction of no fewer than nine biologic agents with distinct [...]

Dr RF van Vollenhoven, S Ernestam, P Geborek, IF Petersson, L Cöster, E Waltbrand, A Zickert, J Theander, Å Thörner, H Hellström, A Teleman, C Dackhammar, F Akre, K Forslind, L Ljung, R Oding, A Chatzidionysiou, M Wörnert, J Bratt Background New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate [...]